| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the UCSF MS Center (Dr. Waubant), San Francisco, CA; and Service de neurologie A and EDMUS Coordinating Center (Drs. Vukusic, Gignoux, Durand-Dubief, Achiti, Blanc, Renoux, and Confavreux), Hôpital neurologique, Lyon, France.
Address correspondence and reprint requests to Dr. E. Waubant, UCSF MS Center, 350 Parnassus St., Suite 908, San Francisco, CA 94117; e-mail: waubant{at}itsa.ucsf.edu
Objective: To determine the proportion of patients with multiple sclerosis (MS) who respond to interferon-ß (IFNB) therapy and assess whether clinical characteristics differ in IFNB responders vs nonresponders.
Methods: Data on all patients who received IFNB who were entered in the prospective European Database for Multiple Sclerosis (EDMUS) database in Lyon as of March 31, 2001, were reviewed. Responders were defined as having a lower relapse rate on IFNB compared with the year or 2 years prior to IFNB therapy.
Results: Two hundred sixty-two patients with relapsing MS received at least 6 months of IFNB: 200 relapsing remitting (RR) and 62 relapsing secondary progressive (SP). One-third of patients experienced a higher or identical annual relapse rate while on IFNB treatment. Compared with nonresponders, responders were older and had longer disease duration at the time IFNB was initiated. RRMS responders also had a higher relapse rate during the year prior to IFNB therapy and SPMS responders had a higher Disability Status Scale score at initiation of IFNB.
Conclusion: Clinical profiles of patients with relapsing MS who respond to IFNB may differ from those who do not with a more inflammatory and less neurodegenerative disease at the time IFNB is initiated.
This article has been cited by other articles:
|
|
 |
|
  J Rio, J Castillo, A Rovira, M Tintore, J Sastre-Garriga, A Horga, C Nos, M Comabella, X Aymerich, and X Montalban Measures in the first year of therapy predict the response to interferon {beta} in MS Multiple Sclerosis, July 1, 2009; 15(7): 848 - 853. [Abstract] [PDF]
|
|
|
|
 |
|
 M Hutchinson Predicting and preventing the future: actively managing multiple sclerosis Practical Neurology, June 1, 2009; 9(3): 133 - 143. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A Gajofatto, P Bacchetti, B Grimes, A High, and E Waubant Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis Multiple Sclerosis, January 1, 2009; 15(1): 50 - 58. [Abstract] [PDF]
|
|
|
|
 |
|
 A. W. Chiu, N. Richert, M. Ehrmantraut, J. Ohayon, S. Gupta, G. Bomboi, D. Gaindh, F. K. Cantor, J. A. Frank, H. F. McFarland, et al. Heterogeneity in Response to Interferon Beta in Patients With Multiple Sclerosis: A 3-Year Monthly Imaging Study Arch Neurol, January 1, 2009; 66(1): 39 - 43. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I Bosca, F Coret, C Valero, A. Pascual, M. Magraner, L Landete, and B Casanova Effect of relapses over early progression of disability in multiple sclerosis patients treated with beta-interferon Multiple Sclerosis, June 1, 2008; 14(5): 636 - 639. [Abstract] [PDF]
|
|
|
|
 |
|
 L Durelli, P Barbero, M Bergui, E Versino, M A Bassano, E Verdun, C Rivoiro, C Ferrero, E Picco, P Ripellino, et al. MRI activity and neutralising antibody as predictors of response to interferon {beta} treatment in multiple sclerosis J. Neurol. Neurosurg. Psychiatry, June 1, 2008; 79(6): 646 - 651. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J Rio, A Rovira, M Tintore, E Huerga, C Nos, N Tellez, C Tur, M Comabella, and X Montalban Relationship between MRI lesion activity and response to IFN-{beta} in relapsing-remitting multiple sclerosis patients Multiple Sclerosis, May 1, 2008; 14(4): 479 - 484. [Abstract] [PDF]
|
|
|
|
 |
|
 J. Sepulcre, M. Murie-Fernandez, A. Salinas-Alaman, A. Garcia-Layana, B. Bejarano, and P. Villoslada Diagnostic accuracy of retinal abnormalities in predicting disease activity in MS Neurology, May 1, 2007; 68(18): 1488 - 1494. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. O'Rourke, C. Walsh, G. Antonelli, and M. Hutchinson Predicting beta-interferon failure in relapsing-remitting multiple sclerosis Multiple Sclerosis, April 1, 2007; 13(3): 336 - 342. [Abstract] [PDF]
|
|
|
|
|
|
S Martinez-Yelamos, A Martinez-Yelamos, G M. Ozaeta, V Casado, O Carmona, and T. Arbizu Regression to the mean in multiple sclerosis Multiple Sclerosis, November 1, 2006; 12(6): 826 - 829. [Abstract] [PDF]
|
|
|
|
|
|
K. Chadha, B. Weinstock-Guttman, R. Zivadinov, K. Bhasi, J. Muhitch, J. Feichter, M. Tamano-Blanco, N. Abdelrahman, J. Ambrus Sr, F. Munschauer, et al. Interferon Inhibitory Activity in Patients With Multiple Sclerosis Arch Neurol, November 1, 2006; 63(11): 1579 - 1584. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Trojano, P. Russo, A. Fuiani, D. Paolicelli, E. Di Monte, E. Granieri, G. Rosati, G. Savettieri, G. Comi, P. Livrea, et al. The Italian Multiple Sclerosis Database Network (MSDN): the risk of worsening according to IFN{beta} exposure in multiple sclerosis Multiple Sclerosis, September 1, 2006; 12(5): 578 - 585. [Abstract] [PDF]
|
|
|
|
|
|
E Portaccio, V Zipoli, G Siracusa, S Sorbi, and M P Amato Response to interferon-beta therapy in relapsing-remitting multiple sclerosis: a comparison of different clinical criteria Multiple Sclerosis, June 1, 2006; 12(3): 281 - 286. [Abstract] [PDF]
|
|
|
|
|
|
S L Minden, D Frankel, L Hadden, J Perloff, K P Srinath, and D C Hoaglin The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics Multiple Sclerosis, February 1, 2006; 12(1): 24 - 38. [Abstract] [PDF]
|
|
|
|
|
|
P. Villoslada, J. R. Oksenberg, J. Rio, X. Montalban, E. L. Waubant, S. Vukusic, and C. Confavreux Clinical characteristics of responders to interferon therapy for relapsing MS Neurology, May 11, 2004; 62(9): 1653 - 1653. [Full Text] [PDF]
|
|
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
